Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 9/20 | 0.52 |
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095781 | 1.00 | EEF2K (0.52) | EEF2KIKBKBBRAFHSP90AB1HTT | |
| SCHEMBL3095791 | 1.00 | EEF2K (0.52) | EEF2KIKBKBBRAFHSP90AB1HTT | |
| SCHEMBL13885056 | 0.90 | EEF2K (0.56) | EEF2KIKBKBBRAFHTTALDH1A1 | |
| SCHEMBL14312223 | 0.89 | EEF2K (0.40) | EEF2KIKBKBBRAF | |
| SCHEMBL14312487 | 0.89 | EEF2K (0.40) | EEF2KIKBKBBRAF | |
| SCHEMBL3092018 | 0.88 | EEF2K (0.55) | EEF2KIKBKBBRAFHSP90AB1HTT | |
| SCHEMBL3088349 | 0.87 | EEF2K (0.54) | EEF2KIKBKBBRAFHSP90AB1HTT | |
| SCHEMBL3076839 | 0.86 | EEF2K (0.52) | EEF2KIKBKBBRAFHSP90AB1HTT | |
| SCHEMBL3101500 | 0.86 | EEF2K (0.53) | EEF2KIKBKBBRAFHSP90AB1ALDH1A1 | |
| SCHEMBL3076870 | 0.85 | IKBKB (0.54) | EEF2KIKBKBBRAFHSP90AB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197886-B1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2197886-B1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009049743-A1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | TGFBR1, TGFBR2, ACVR1 | EEF2K 2875/4885IKBKB 599/4885BRAF 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.